Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Selinexor (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms SABLe
- 19 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2023 Planned number of patients changed from 100 to 50.
- 16 May 2021 Status changed from not yet recruiting to recruiting.